Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547748 | 0.96 | TBK1 (0.43) | TBK1CYP4F2GPR119PIK3CDALK | |
| SCHEMBL20120729 | 0.96 | TBK1 (0.43) | TBK1CYP4F2GPR119PIK3CDALK | |
| SCHEMBL20120731 | 0.96 | TBK1 (0.43) | TBK1CYP4F2GPR119PIK3CDALK | |
| SCHEMBL20128900 | 0.96 | TBK1 (0.43) | TBK1CYP4F2GPR119PIK3CDALK | |
| SCHEMBL20120441 | 0.86 | GPR119 (0.51) | TBK1GPR119PIK3CDNAMPT | |
| SCHEMBL29547262 | 0.86 | GPR119 (0.51) | TBK1GPR119PIK3CDNAMPT | |
| SCHEMBL31411045 | 0.86 | GPR119 (0.51) | TBK1GPR119PIK3CDNAMPT | |
| SCHEMBL20120443 | 0.86 | GPR119 (0.51) | TBK1GPR119PIK3CDNAMPT | |
| SCHEMBL20128890 | 0.84 | MAPT (0.42) | — | |
| SCHEMBL22906608 | 0.82 | ATM (0.38) | CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | TBK1 195/4885CYP4F2 4477/4885GPR119 3791/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | TBK1 406/4885CYP4F2 4640/4885GPR119 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.